Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

UPDATE 1-UK Stocks-Factors to watch on Feb 22

4h reuters
Feb 22 (Reuters) - Britain’s FTSE 100 index is seen to open 82 points lower at 7,199.8 on Thursday, according to financial bookmakers, with futures down 0.86 percent ahead of the cash market open. (77-0)

Merck-Viralytics Deal: Just Doubling Down On Keytruda - Bloomberg

13h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (54-0)

US health officials reverse stance on AstraZeneca's flu vaccine - Channel NewsAsia

15h channelnewsasia
AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position. (35-0)

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

19h reuters
COPENHAGEN (Reuters) - Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly’s Trulicity. (35-0)

Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix

19h seekingalpha
Today we will discuss Portola Pharmaceuticals (PTLA), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. (227-0)

Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?

20h zacks
We expect Perrigo Company plc (PRGO - Free Report) to beat estimates when it reports fourth-quarter 2017 and full-year results before the opening bell on Feb 27. (61-0)

FDA Accepts Acorda's NDA for Parkinson's Disease Candidate

21h zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that the FDA has accepted its new drug application (NDA) for late stage pipeline candidate, Inbrija. The FDA is expected to give its decision on the candidate on Oct 5, 2018. The company had resubmitted the NDA for Inbrija in December 2017. (53-0)

Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

22h zacks
Ionis Pharmaceuticals, Inc. (IONS - Free Report) announced that it has out-licensed IONIS-AZ5-2.5Rx, a Generation 2.5 antisense drug, to AstraZeneca (AZN - Free Report) . The candidate will be developed to treat a genetically associated form of kidney disease. (122-0)

Nektar And Bristol-Myers Squibb's Deal Could Be An Opportunity For NewLink

2018-02-20 seekingalpha
Nektar and BMY's PIVOT-02 trial provided proof of concept for the synergistic action between PD-1 inhibition and T-Cell proliferation by Nektar’s NKTR-214 with tolerable safety profile. (86-0)

Jeremy Corbyn Has a Point About Bankers - Bloomberg

2018-02-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (52-0)

AZN / AstraZeneca Plc ASTRAZENECA'S IMFINZI APPROVED FOR STAGE III NSCLC (Current Report of Foreign Issuer)

2018-02-20 sec.gov
Blueprint   FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of February 2018   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. (35-0)

AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

2018-02-19 zacks
AstraZeneca (AZN - Free Report) announced that the FDA has approved a second indication for its PD-L1 inhibitor, Imfinzi. It is now approved for unresectable Stage III non-small cell lung cancer (“NSCLC”). The drug is meant for patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (74-0)

AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In

2018-02-19 seekingalpha
AstraZeneca obtains first FDA approval for Imfinzi for stage 3 lung cancer patients with unresectable tumors and those who have not progressed after chemoradiation therapy. (39-0)

Advaxis' Chances: What Can EMA Failures Tell Us About Its Future?

2018-02-19 seekingalpha
In spite of this, the company has achieved a monumental goal of submitting for marketing authorization with the EMA. (194-0)

UPDATE 1-UK Stocks-Factors to watch on Feb 19

2018-02-19 reuters
Feb 19 (Reuters) - Britain’s FTSE 100 index is seen opening 12 points higher at 7,306.4 on Monday, according to financial bookmakers, with futures up 0.20 percent ahead of the cash market open. (35-0)


CUSIP: 046353108